Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027586 · ClinicalTrials.gov registry record · Phase 2
Imatinib Mesylate in Treating Patients With Metastatic Melanoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00027586: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00027586 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00027586, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for metastatic melanoma. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have metastatic melanoma.
Interventions
- DRUG Imatinib mesylate (STI571)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2001-09 |
| Est. Completion | 2005-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00027586
The ClinicalTrials.gov registry entry for NCT00027586 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Imatinib mesylate (STI571) is the first listed.
NCT00027586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00027586 about?
NCT00027586 is a clinical study titled "Imatinib Mesylate in Treating Patients With Metastatic Melanoma". RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for metastatic melanoma. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have metastatic melanoma.
What is the current status of trial NCT00027586?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2001-09. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00027586?
The interventions under investigation include: Imatinib mesylate (STI571) (DRUG).
Who is sponsoring clinical trial NCT00027586?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.